Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Avidity Biosciences Inc (Avidity Biosciences), a subsidiary of Novartis AG, is a biotechnology company that focuses on the development of RNA therapeutics. It offers proprietary AOCs that combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address diseases previously unreachable with existing RNA treatments. The company’s pipeline products include Del-desiran, which treats myotonic dystrophy type 1 (DM1); Del-zota, for duchenne muscular dystrophy (DMD); Del-brax, which targets facioscapulohumeral muscular dystrophy (FSHD); AOC 1045, for duchenne muscular dystrophy (DMD) Exon 45; AOC 1086, which treats PLN Cardiomyopathy and AOC 1072, which targets PRKAG2 Syndrome. Avidity Biosciences is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3020 Callan Road, San Diego, California, 92121
Website
www.aviditybiosciences.com
Telephone
1 858 4017900
No of Employees
511
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$18.8M
Products and Services
| Products |
|---|
| Pipeline |
| AOC 1072: PRKAG2 Syndrome |
| Del-zota: Duchenne Muscular Dystrophy (DMD) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into an agreement to be acquired by Novartis AG. |
| 2021 | Contracts/Agreements | In January, the company entered into a research collaboration with MyoKardia to initiate a Phase 1/2 clinical study of AOC 1001 in adults with myotonic dystrophy type 1. |
| 2020 | Plans/Strategy | In May, the company announced its plans to raise IPO of shares. |
Competitor Comparison
| Key Parameters | Avidity Biosciences Inc | Sanofi | Vertex Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Sarepta Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | France | United States of America | United States of America | United States of America |
| City | San Diego | Paris | Boston | Cambridge | Cambridge |
| State/Province | California | Ile-de-France | Massachusetts | Massachusetts | Massachusetts |
| No. of Employees | 511 | 76,493 | 6,400 | 2,500 | 835 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Troy Wilson, Ph.D | Chairman | Executive Board | 2012 | 56 |
| Sarah Boyce | Director; President; Chief Executive Officer | Executive Board | 2019 | 53 |
| Michael MacLean | Chief Financial Officer | Senior Management | 2022 | 59 |
| Steve Hughes, MDs | Chief Medical Officer | Senior Management | 2022 | - |
| W. Michael Flanagan, PhD | Chief Scientific Officer | Senior Management | 2023 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer